Philips ships advanced MRI package

Article

Philips Medical Systems North America of Shelton, CT, has received Food and Drug Administration clearance for a new MRI upgrade package that includes high-end features such as cardiac scanning protocols and neuro imaging techniques. The package is

Philips Medical Systems North America of Shelton, CT, has received Food and Drug Administration clearance for a new MRI upgrade package that includes high-end features such as cardiac scanning protocols and neuro imaging techniques. The package is available on the company’s Gyroscan NT line of magnets.

In the neuro imaging realm, the new package includes an option supporting diffusion, perfusion, and functional brain imaging, which can help in the early detection of stroke. On the cardiac side, the package enables a Gyroscan NT site to conduct cardiac MRI without purchasing additional hardware. One feature of the package, MotionTrak, enables users to control motion artifacts through gating and slice tracking. Other features of the new package include advancements in MR angiography, MR spectroscopy, and coil technology.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.